Septerna, Inc. (NASDAQ:SEPN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Septerna, Inc. (NASDAQ:SEPN) has been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $55.22.

Several equities research analysts have recently commented on SEPN shares. Guggenheim boosted their target price on shares of Septerna from $51.00 to $65.00 and gave the company a “buy” rating in a research note on Friday. Raymond James Financial reiterated a “strong-buy” rating and set a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. HC Wainwright lifted their price target on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Wells Fargo & Company boosted their price target on shares of Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a research report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research report on Wednesday, August 19th.

Insider Buying and Selling

In other news, SVP Daniel D. Long sold 3,333 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total value of $126,087.39. Following the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,647,265.96. The trade was a 3.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $37.41, for a total value of $149,640.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $6,517,158.69. This trade represents a 2.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

A number of institutional investors and hedge funds have recently bought and sold shares of SEPN. TRV GP V LLC acquired a new stake in shares of Septerna in the second quarter valued at $208,160,143. TRV GP VI LLC bought a new position in shares of Septerna in the second quarter valued at about $141,048,460. BlackRock Inc. acquired a new position in Septerna during the 2nd quarter worth about $64,706,000. Jupiter Topco LLC acquired a new position in Septerna during the 2nd quarter worth about $43,723,000. Finally, Primecap Management Co. CA acquired a new position in Septerna during the 2nd quarter worth about $39,096,000.

Septerna Trading Up 3.9%

Shares of SEPN opened at $50.74 on Thursday. Septerna has a 1 year low of $17.98 and a 1 year high of $51.10. The stock has a 50 day simple moving average of $39.76 and a 200-day simple moving average of $32.71. The stock has a market cap of $2.37 billion, a PE ratio of -93.96 and a beta of 2.20.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.15). Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The company had revenue of $18.88 million during the quarter, compared to analyst estimates of $20.78 million. On average, sell-side analysts forecast that Septerna will post -1.41 EPS for the current fiscal year.

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development.